LEXINGTON, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches for the treatment of T2D and obesity, announced the nomination ...

Next anticipated Revita® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 ...

Authorization advances Fractyl Health to a dual clinical-stage company, with Revita® in pivotal development for post-GLP-1 weight maintenance and ...

Fractyl Health’s GLP-1-based pancreatic gene therapy has outperformed semaglutide injections for weight loss—at least in mice. In a presentation Oct. 4 at the annual conference of the European ...

With the gold rush in obesity meds showing no sign of abating, Fractyl Health is gearing up to go public as it gathers preclinical evidence that its GLP-1 gene therapy could take on Novo Nordisk’s ...

(Reuters) - Shares of Fractyl Health fell 8.3% on their market debut on Friday, giving the obesity and diabetes drug developer a market capitalization of $654.6 million. After a two-year lull, initial ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today ...

Fractyl Health, Inc. (NASDAQ:GUTS) is one of the 10 Best New Penny Stocks to Invest In. On December 19, Canaccord Genuity reiterated its Buy rating on Fractyl Health, Inc. (NASDAQ:GUTS) with a price ...

We recently published a list of 10 Micro-Cap Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where Fractyl Health, Inc. (NASDAQ:GUTS) stands against other micro ...

There’s no shortage of unpleasant surprises in medicine, but every now and then the die roll in humanity’s favor. One recent example: bariatric surgery. Originally designed for weight loss, experts ...